(Cardinal Health) June 10, 2021 – The new indication will provide accurate and precise lymph node identification in pediatric patients one month and older with melanoma, rhabdomyosarcoma or other types of solid tumors.
Cardinal Health™ Nuclear & Precision Health Solutions Receives U.S. Food and Drug Administration Approval for New LYMPHOSEEK® Pediatric Indication
by MM360 Staff | Jun 10, 2021 | Uncategorized | 0 comments